Novel PCR Testing Device Represents Technological Leap in POC Infectious Disease Diagnostics
By LabMedica International staff writers Posted on 15 May 2023 |
Testing for infectious diseases is vital for global health. Present testing methods, including immunochemistry and nucleic acid detection, play a crucial role in combating infectious diseases, but they also have significant drawbacks. Consequently, healthcare providers and patients often have to choose between fast and affordable results with limited sensitivity, or slower, more accurate results which often arrive too late to significantly impact outcomes. This situation often leads to lost opportunities for more effective treatment of infectious diseases. Now, a novel testing device offers a significant advancement in point-of-care infectious disease testing, potentially expanding the scope of telemedicine interactions between healthcare professionals and their patients.
Nuclein’s (Austin, TX, USA) Anywhere PCR Test is a PCR testing device designed to run a real-time PCR reaction inside an all-in-one self-test, infectious disease testing solution and delivers battery-powered, sample-to-answer results in less than an hour. This allows immediate, self-testing results to be available anywhere at the push of a button, utilizing the same standard real-time PCR technology employed by the U.S. Centers for Disease Control and Prevention (CDC), other government bodies, and commercial laboratories.
The testing device is designed to accept a saliva sample directly from the patient. The diagnostic process can be initiated by simply pressing a button, after which the device automatically prepares the sample for analysis. Test results are then automatically displayed on the LCD screen within an hour, indicating either a negative or positive result. The capacity to provide immediate results in less than an hour potentially makes the Nuclein Anywhere PCR Test an exceptionally useful tool for detecting infectious diseases, facilitating faster and more informed decision-making, ultimately leading to improved outcomes.
Related Links:
Nuclein
Latest Molecular Diagnostics News
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
- Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms